Xilio Therapeutics (XLO) Revenue (2024 - 2026)

Xilio Therapeutics has disclosed Revenue across 3 years of filings, most recently posting $18.7 million for Q2 2026.

• In Q2 2026, Revenue rose 131.22% year-over-year to $18.7 million; the TTM figure through Jun 2026 stood at $64.1 million (up 327.25% YoY), while the FY2025 annual figure was $43.8 million, up 589.88% from the prior year.
• Revenue came in at $18.7 million for Q2 2026 at Xilio Therapeutics, up from $12.6 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $19.1 million in Q3 2025 to a low of $1.7 million in Q4 2024.
• Average Revenue over 3 years is $9.0 million, with a median of $8.1 million recorded in 2025.
• Year-over-year, Revenue surged 742.51% in 2025 and surged 131.22% in 2026.
• Over 3 years, Revenue stood at $1.7 million in 2024, then surged by 693.85% to $13.7 million in 2025, then jumped by 36.58% to $18.7 million in 2026.
• Per Business Quant data, the three most recent Revenue figures were $18.7 million in Q2 2026, $12.6 million in Q1 2026, and $13.7 million in Q4 2025.